Introduction: Pembrolizumab is a humanised monoclonal antibody targeting the receptor programmed cell death protein-1 (PD-1), with anti-tumour activity demonstrated for many malignancies. Such immune checkpoint inhibitors are associated with many immune-related adverse events including rash, colitis, hepatitis, pneumonitis, endocrinopathy and, rarely, haematological adverse events, including immune-related thrombocytopenia. Case report: We report a 60-year-old female with metastatic non-small cell lung cancer treated with pembrolizumab every three weeks. Following her fifth cycle, she presented to our hospital with community-acquired pneumonia. Thrombocytopenia developed the next day and, after detailed investigations, thrombotic thrombocytopenic purpura was diagnosed. Management and outcome: Pembrolizumab was immediately ceased and plasma exchange commenced along with IV methylprednisolone 250 mg daily for three days followed by oral prednisolone. After five days of plasma exchange, platelet counts normalised and haemolytic anaemia resolved. Discussion: Acquired thrombotic thrombocytopenic purpura is an autoimmune disorder caused by an inhibitory autoantibody against ADAMTS-13. While most cases of acquired thrombotic thrombocytopenic purpura are idiopathic, certain conditions (e.g. bacterial infection, autoimmune disorders, malignancies) and medications are associated with thrombotic thrombocytopenic purpura. Other potential causes were eliminated in our patient. As acquired thrombotic thrombocytopenic purpura is an autoimmune disorder, pembrolizumab, given its unique mechanism of action and association with immune-related adverse events, is believed to be implicated in the development of thrombotic thrombocytopenic purpura. This case is one of only two linking anti-PD-1 therapy to thrombotic thrombocytopenic purpura development (the other occurring in a patient on nivolumab plus ipilimumab). Thrombotic thrombocytopenic purpura is life-threatening and clinicians are advised to be aware of its possible occurrence in immune checkpoint inhibitor-treated patients.
16 December 2022 in International Journal of Infectious Diseases
To determine if shorter courses of antibiotic therapy for group A Streptococcus (GAS) bacteremia are associated with excess mortality. In this retrospective study of consecutive cases of GAS bacteremia in tropical Australia, the duration of antibiotic therapy was correlated with 90-day all-cause mortality. There were 286 episodes of GAS bacteremia; the patients' median (interquartile range) age was 60 (48-71) years and 169/286 (59.1%) patients identified as an Indigenous Australian. There were 227/286 (79.4%) patients with a significant comorbidity. The all-cause 90-day mortality was 16/286 (5.6%); however, 12/16 (81.3%) patients died while still receiving their initial course of antibiotics and only 7/16 (43.8%) deaths were directly attributable to the GAS infection. After excluding patients who died while taking their initial course of antibiotics and those in whom the duration of therapy was uncertain, there was no difference in 90-day mortality between patients receiving ≤5 days of intravenous antibiotics and those receiving longer courses (1/137 [0.7%] vs 3/107 [2.8%], P-value = 0.32) nor in patients receiving ≤10 days of total therapy and those receiving longer courses (1/67 [1.5%] vs 3/178 [1.7%], P-value = 1.0). Even among patients with significant comorbidity, shorter antibiotic courses for GAS bacteremia are not associated with excess mortality.
1 July 2023 in Turkish Journal of Emergency Medicine
Staphylococcus schleiferi bacteremia is an underappreciated cause of septic shock in the critical care department. Although nominally a coagulase variable Staphylococcus and associated with otitis externa infections in canine species, it has been associated with the metastatic infection including osteomyelitis, endocarditis, nephritis, and meningitis in humans. This report records a possible zoonotic case of S. schleiferi subspecies coagulans bacteremia following canine otitis externa associated with septic shock and endovascular infection precipitating intensive care admission for vasopressor support in an immunocompetent male.
2 July 2025 in The Lancet Regional Health - Western Pacific
Aboriginal and Torres Strait Islander (hereafter respectfully named Indigenous) Australians are diagnosed with some cancers substantially more frequently than non-Indigenous Australians implying a different risk factor landscape. Additionally, poorer outcomes for certain cancers are exacerbated by lower cancer screening rates and later diagnoses compared to non-Indigenous Australians. An improved understanding of cancer causation would allow better shaping and targeting of screening programs for those at the highest risk. A narrative review of relevant environmental and genetic risk factors for various cancers in Indigenous populations was undertaken. Research databases were interrogated in June 2024, with information extracted. Further peer-reviewed and grey literature was identified by specific searchers and citation snowballing. The results show that many distinct risk factors exist in environmental, sociocultural, educational, behavioural and metabolic domains; these complex and frequently interacting risks include direct and indirect social and cultural factors. Identified gaps include limited published literature on the genetic determinants of cancer, decreased levels of effective cancer surveillance for Indigenous Australians, a paucity of culturally appropriate cancer health education programs for both Indigenous community members and health providers, and the historical absence of an Indigenous Australian focus and contribution to research on cancer causation. Indigenous Australian co-designed research is needed to address the gaps contributing to cancer prevention and screening development. Empowerment of national Indigenous Australian leadership in partnership with researchers and service providers is needed to develop tailored health interventions and reduce the existing and future challenges of the cancer burden on Indigenous communities.
Group A Streptococcus (GAS) bacteraemia is common in tropical settings and has a high case-fatality rate. Early recognition of the high-risk patient can expedite the escalation of care. We examined consecutive episodes of GAS bacteraemia in Far North Queensland, tropical Australia between January 1, 2014, and December 31, 2020. The patients' demographics and clinical and laboratory indices at presentation were correlated with their subsequent clinical course. There were 286 episodes of GAS bacteraemia. The patients' median (interquartile range) age at presentation was 60 (48-71) years, 154 (53.9%) were male, 169 (59.1%) identified as a First Nations Australian, 126 (44.1%) had severe comorbidity and 136 (47.6%) lived in a remote location. There were 50/286 (17.5%) who died or were admitted to the intensive care unit (ICU) admission within 30 days of hospitalisation. In multivariable analysis, systolic blood pressure <100 mmHg (adjusted odds ratio (aOR) (95% confidence interval (CI)): 5.67 (2.20 - 14.55), p4 mmol/L (aOR (95% CI)): 5.32 (1.92 - 14.72), p=0.001), a circulating lymphocyte count <0.5×109/L (aOR (95% CI)): 2.68 (1.17 - 6.12) p=0.02) and a serum albumin <30 g/L (aOR (95% CI)): 2.24 (1.01 - 4.97), p= 0.049) at presentation were independent predictors of death or ICU admission within 30 days. There were 21/286 (7%) with a diagnosis of streptococcal toxic shock syndrome (STSS) and necrotising fasciitis; all 21 died or required ICU admission. Individuals with a diagnosis of STSS and/or necrotising fasciitis were more likely to die within 30 days than the individuals without STSS or necrotising fasciitis (8/21 (38.1%) versus 13/272 (4.8%), OR (95%): 26.56 (8.03 - 87.86), p < 0.0001). Patients with GAS bacteraemia who have hypotension, raised serum lactate, lymphopenia and hypoalbuminaemia at presentation are at greater risk of a complicated course. Individuals with STSS and necrotising fasciitis are at the greatest risk of death, emphasising the importance of considering - and actively excluding - these diagnoses in the appropriate clinical context.
Key Clinical Message: Consider the differential of Epstein–Barr virus (EBV) reactivation in pregnant women who develop progressive meningoencephalitis and transverse myelitis. EBV nucleic acid amplification should be considered in immunosuppressed patients. A 32‐year‐old G10P6M3K22 pregnant female presented to a regional hospital with progressive severe neurological and behavioral deficits. Magnetic resonance revealed cervical transverse myelitis. Lumbar puncture confirmed Epstein–Barr virus (EBV) DNA on a background of IgG‐positive EBV serology. A diagnosis of EBV reactivation‐related meningoencephalitis with transverse myelitis in pregnancy was concluded.